Search form
Search
contact us
Navigation
home
boards
job center
job ratings
cp wire
device news
pharmagather
catering
advertise
Legal Help
login/register
You are here
Home
»
companies
» earnings
earnings
Medtech’s haves and have-nots
Medtech’s haves and have-nots
EP Vantage
earnings
devices
Medtech
Medtronic
EXACT Sciences
Thermo Fisher
Abbott Labs
Roche
Qiagen
JNJ
Zimmer Biomet
Smith & Nephew
Boston Scientific
Flag link:
Medtronic Gains Momentum in Diabetes
Medtronic Gains Momentum in Diabetes
Medical Devices and Diagnostics Industry
Medtronic
earnings
devices
diabetes
Flag link:
Here's What I'll Be Looking for in Moderna's Earnings Report Next Week
Here's What I'll Be Looking for in Moderna's Earnings Report Next Week
Motley Fool
Moderna Therapeutics
earnings
Flag link:
Pharma’s pipeline continues to provide drama as investors look beyond COVID in Q4
Pharma’s pipeline continues to provide drama as investors look beyond COVID in Q4
Pharmaforum
pharma industry
R&D
pandemic
earnings
COVID-19
Biogen
GW Pharma
Jazz Pharmaceuticals
GSK
Merck KGaA
Flag link:
GW Pharmaceuticals Beats on Revenue, Bottom Line for Q4
GW Pharmaceuticals Beats on Revenue, Bottom Line for Q4
Motley Fool
GW Pharma
earnings
Flag link:
Exact Sciences Falls in After-Hours Trading on Q4 Results
Exact Sciences Falls in After-Hours Trading on Q4 Results
Motley Fool
EXACT Sciences
earnings
Flag link:
The Week Ahead In Biotech: FDA Decision On G1 Therapeutics, Earnings In The Mix For Light Calendar Week
The Week Ahead In Biotech: FDA Decision On G1 Therapeutics, Earnings In The Mix For Light Calendar Week
Yahoo/Benzinga
earnings
FDA
G1 Therapeutics
trilaciclib
Zoetis
EXACT Sciences
Blueprint Medicines
Ironwood Pharmaceuticals
Flag link:
3 Q4 takeaways: COVID-19 testing strong (for now), electives hit, and M&A
3 Q4 takeaways: COVID-19 testing strong (for now), electives hit, and M&A
Medtech Dive
devices
earnings
COVID-19
pandemic
Flag link:
Why Alkermes' Q4 Results Were Better Than They Might Seem
Why Alkermes' Q4 Results Were Better Than They Might Seem
Motley Fool
Alkermes
earnings
Flag link:
How Pacific Biosciences Beat Expectations in Q4
How Pacific Biosciences Beat Expectations in Q4
Motley Fool
Pacific Biosciences
earnings
Flag link:
What's Behind Incyte's Better-Than-Expected Q4 Earnings
What's Behind Incyte's Better-Than-Expected Q4 Earnings
Motley Fool
Incyte
earnings
Flag link:
Sanofi flunks Parkinson's Phase II, axes handful of mid-stage programs in Q4 earnings
Sanofi flunks Parkinson's Phase II, axes handful of mid-stage programs in Q4 earnings
Endpoints
Sanofi
earnings
Parkinson's Disease
drug development
Flag link:
Veklury rescues Gilead from COVID doldrums in Q4
Veklury rescues Gilead from COVID doldrums in Q4
Pharmaforum
Gilead Sciences
Veklury
earnings
Flag link:
Coronavirus uncertainty clouds Quest's 2d half amid Q4 revenue bump
Coronavirus uncertainty clouds Quest's 2d half amid Q4 revenue bump
Medtech Dive
Quest Diagnostics
diagnostics
earnings
COVID-19
Flag link:
How Bristol Myers Squibb's Celgene Buyout Continued to Pay Off in Q4
How Bristol Myers Squibb's Celgene Buyout Continued to Pay Off in Q4
Motley Fool
Bristol-Myers Squibb
Celgene
earnings
M&A
Flag link:
Merck Misses Q4 Earnings Forecast
Merck Misses Q4 Earnings Forecast
TheStreet.com
Merck
earnings
Flag link:
Glaxo (GSK) Q4 Earnings Lag Estimates, Shingrix Back on Track
Glaxo (GSK) Q4 Earnings Lag Estimates, Shingrix Back on Track
Yahoo/Zacks.com
GSK
earnings
Flag link:
Roche chucks out phase 3 ipatasertib combo tests, midstage IL-33 asthma, BTKi arthritis trials in Q4 clear-out
Roche chucks out phase 3 ipatasertib combo tests, midstage IL-33 asthma, BTKi arthritis trials in Q4 clear-out
Fierce Biotech
Roche
earnings
cancer
autoimmune disease
drug development
Flag link:
AbbVie's immunology newbies Skyrizi and Rinvoq pick up the slack from declining Humira, but safety questions dog execs
AbbVie's immunology newbies Skyrizi and Rinvoq pick up the slack from declining Humira, but safety questions dog execs
Fierce Pharma
AbbVie
FDA
Skyrizi
Rinvoq
Humira
earnings
Flag link:
Biogen laser-focused on Alzheimer's drug as rest of business falters
Biogen laser-focused on Alzheimer's drug as rest of business falters
BioPharma Dive
Biogen
earnings
aducanumab
Alzheimer's disease
Flag link:
Pages
1
2
3
4
5
6
7
8
9
…
next ›
last »